FREE TOOL · LIVE DATA

HALO DCF Calculator

Run your own discounted cash flow valuation for Halozyme Therapeutics. The calculator is pre-filled with real data — $0.6B free cash flow (FY2025) and the live share price — so you only adjust the assumptions.

SEARCH STOCK

Search to auto-fill real company data

COMPANY DATA

Annual, in billions
$B
In billions
B
Per share
$

YOUR ASSUMPTIONS

Projected
%
Required return
%
yrs
Perpetuity
%

YOUR DCF RESULT

CALCULATED FAIR VALUE

$126.22

14.3% upsideUNDERVALUED

MARKET

$108.17

YOUR DCF

$126.22

MARGIN

$18.05

VALUE BREAKDOWN

PV of Projected Cash Flows$6.4B
PV of Terminal Value
$8.7B58% of total
Total Enterprise Value$15.1B
÷ Shares Outstanding0.12B
Fair Value Per Share$126.22

SENSITIVITY CHECK

Try adjusting growth rate by ±2% and discount rate by ±1% to see how sensitive your fair value is to assumptions.

COMPARE WITH FPI FAIR VALUE

Your DCF reflects your assumptions. As an independent reference, here is Fair Price Index's daily blended fair value for Halozyme Therapeutics — DCF (50%), relative valuation (30%), and analyst consensus (20%):

HALO · FPI MODELLIVE DATA · UPDATED DAILY
HALOHalozyme Therapeutics
$108.17fair $139.09-22.2% below fair value
See the full HALO valuation breakdown →

Frequently Asked Questions

What is HALO's free cash flow?

Halozyme Therapeutics generated $0.6 billion of free cash flow in fiscal year 2025. That figure is pre-filled in the calculator above and refreshed daily.

How do I calculate HALO's fair value with a DCF?

Project Halozyme Therapeutics's free cash flow forward at your assumed growth rate, discount each year back at your required return (WACC), add a terminal value, and divide by shares outstanding. The calculator above does all of this instantly as you adjust the assumptions.

What growth rate should I use for HALO?

Anchor on history and sector reality: look at Halozyme Therapeutics's revenue and cash flow growth over the past five to ten years, then ask what is sustainable going forward. Testing a conservative and an optimistic scenario matters more than any single number.

Is HALO undervalued right now?

That depends on the assumptions you feed the model — that is the point of running your own DCF. For an independent reference, Fair Price Index publishes a daily fair value for Halozyme Therapeutics blending DCF, relative valuation, and analyst consensus.

GET ALERTS

Track HALO's fair value daily

Download Fair Price Index and get notified when Halozyme Therapeutics's valuation shifts.

Download on the App StoreGet it on Google Play

Trusted by 500+ investors · Free tier available · PRO $2.99/month

RELATED

STOCK

HALO Stock Analysis

Full fair value breakdown, FPI Rating, and fundamentals for Halozyme Therapeutics.

Open →

TOOL

DCF Calculator

The general-purpose version — search any of the top 10K stocks.

Open →

ARTICLE

DCF Model Explained

How discounted cash flow works, step by step, with worked examples.

Read →

This calculator is for educational purposes only and does not constitute investment advice. Pre-filled figures come from the latest reported financials and may differ from other sources. Always verify against the company's filings.